Provided is a hepatitis B treatment vaccine based on an inactivated whole recombinant Hansenula polymorpha cell which expresses HBsAg and HBcAg. An HBsAgVLP and an HBcAgVLP expressed in the recombinant Hansenula polymorpha cell are used as antigens, the amino acid sequence of the HBsAg expressed by the recombinant Hansenula polymorpha contains a total of 19 CTL epitopes, the amino acid sequence of the HBcAg expressed by the recombinant Hansenula polymorpha contains a total of 19 CTL epitopes, and the inactivated whole recombinant Hansenula polymorpha cell is used as an adjuvant.
展开▼